Advanced search
Publication Cover
OncoImmunology Volume 12, 2023 - Issue 1
Submit an article Journal homepage
974
Views
0
CrossRef citations to date
0
Altmetric
Commentary

CD40 agonism improves anti-tumor T cell priming induced by the combination of radiation therapy plus CTLA4 inhibition and enhances tumor response

Maud Charpentiera Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USAView further author information
,
Silvia Formentia Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USAView further author information
&
Sandra Demariaa Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA;b Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-4426-0499View further author information
ORCID Icon
Article: 2258011 | Received 05 Sep 2023, Accepted 08 Sep 2023, Published online: 15 Sep 2023

References

  • Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, Demaria S. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti–CTLA-4 antibody. Clin Cancer Res. 2009;15(17):5379–3. doi:10.1158/1078-0432.CCR-09-0265.
  • Formenti SC, Rudqvist N-P, Golden E, Cooper B, Wennerberg E, Lhuillier C, Vanpouille-Box C, Friedman K, Ferrari de Andrade L, Wucherpfennig KW, et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med. 2018;24(12):1845–1851. doi:10.1038/s41591-018-0232-2.
  • Combes AJ, Samad B, Krummel MF. Defining and using immune archetypes to classify and treat cancer. Nat Rev Cancer. 2023;23(7):491–505. doi:10.1038/s41568-023-00578-2.
  • Charpentier M, Spada S, Van Nest SJ, Demaria S. Radiation therapy-induced remodeling of the tumor immune microenvironment. Semin Cancer Biol. 2022;86(Pt 2):737–747. doi:10.1016/j.semcancer.2022.04.003.
  • Rudqvist NP, Charpentier M, Lhuillier C, Wennerberg E, Spada S, Sheridan C, Zhou XK, Zhang T, Formenti SC, Sims JS, et al. Immunotherapy targeting different immune compartments in combination with radiation therapy induces regression of resistant tumors. Nat Commun. 2023;14(1):5146. doi:10.1038/s41467-023-40844-3.
  • Andreatta M, Corria-Osorio J, Müller S, Cubas R, Coukos G, Carmona SJ. Interpretation of T cell states from single-cell transcriptomics data using reference atlases. Nat Commun. 2021;12(1):2965. doi:10.1038/s41467-021-23324-4.
  • Vonderheide RH. CD40 agonist antibodies in cancer immunotherapy. Annu Rev Med. 2020;71(1):47–58. doi:10.1146/annurev-med-062518-045435.
  • Dixon-Douglas J, Loibl S, Denkert C, Telli M, Loi S. Integrating immunotherapy into the treatment landscape for patients with triple-negative breast cancer. Am Soc Clin Oncol Educ Book. 2022;42(42):47–59. doi:10.1200/EDBK_351186.
  • Padron LJ, Maurer DM, O’Hara MH, O’Reilly EM, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP, et al. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat Med. 2022;28(6):1167–1177. doi:10.1038/s41591-022-01829-9.
  • Lax BM, Palmeri JR, Lutz EA, Sheen A, Stinson JA, Duhamel L, Santollani L, Kennedy A, Rothschilds AM, Spranger S, et al. Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies. Proc Natl Acad Sci U S A. 2023;120(31):e2300895120. doi:10.1073/pnas.2300895120.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.